Spruce Biosciences, Inc. (SPRB)
After hours:
| Previous close | 0.7010 |
| Open | 0.7000 |
| Bid | 0.6977 x 400 |
| Ask | 0.7117 x 200 |
| Day's range | 0.6873 - 0.7112 |
| 52-week range | 0.6790 - 5.9500 |
| Volume | |
| Avg. volume | 1,348,733 |
| Market cap | 28.823M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2023 and provided corporate updates.
- Business Wire
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
SOUTH SAN FRANCISCO, Calif., March 13, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia (CAH) and its CAHptain-205 study of tildacerfont in pediatric classic CAH.
- Business Wire
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., January 30, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 2:40 p.m. ET.
